PT - JOURNAL ARTICLE AU - Kiiru, Susan AU - Maina, John AU - Katana, Japhet AU - Mwaniki, John AU - Asiimwe, Benon B AU - Mshana, Stephen E AU - Keenan, Katherine AU - Gillespie, Stephen H. AU - Stelling, John AU - Kiiru, John AU - Holden, Matthew T G AU - HATUA Consortium TI - Bacterial Etiology of Urinary Tract Infections In patients treated at Kenyan Health Facilities And their resistance towards commonly used antibiotics AID - 10.1101/2022.10.25.22281521 DP - 2023 Jan 01 TA - medRxiv PG - 2022.10.25.22281521 4099 - http://medrxiv.org/content/early/2023/03/14/2022.10.25.22281521.short 4100 - http://medrxiv.org/content/early/2023/03/14/2022.10.25.22281521.full AB - Background Evidence-based empirical antibiotic prescribing requires knowledge of local antimicrobial resistance patterns. The spectrum of pathogens and their susceptibility strongly influences guidelines for empirical therapies for urinary tract infections (UTI) management.Objective This study aimed to determine the prevalence of UTI causative bacteria and their corresponding antibiotic resistance profiles in in three counties of Kenya. Such data could be used to determine the optimal empirical therapy.Methods In this cross-sectional study, urine samples were collected from patients who presented with symptoms suggestive of UTI in the following healthcare facilities; Kenyatta National Hospital, Kiambu Hospital, Mbagathi, Makueni, Nanyuki, Centre for Microbiology Research, and Mukuru Health Centres. Urine cultures were done on Cystine Lactose Electrolyte Deficient (CLED) to isolate UTI bacterial etiologies, while antibiotic sensitivity testing was done using the Kirby-Bauer disk diffusion using CLSI guidelines and interpretive criteria.Results A total of 1,027(54%) uropathogens were isolated from the urine samples of 1898 participants. Staphylococcus spp. and Escherichia coli were the main uropathogens at 37.6% and 30.9 %, respectively. The percentage resistance to commonly used drugs for the treatment of UTI were as follows: trimethoprim (64%), sulfamethoxazole (57%), nalidixic acid(57%), ciprofloxacin (27%), amoxicillin-clavulanic acid (5%), and nitrofurantoin (9%) and cefixime (9%). Resistance rates to broad-spectrum antimicrobials, such as ceftazidime, gentamicin, and ceftriaxone, were 15%, 14%, and 11%, respectively. Additionally, the proportion of Multidrug-resistant (MDR) bacteria was 66%.Conclusion High resistance rates toward fluoroquinolones, sulfamethoxazole, and trimethoprim were reported. These antibiotics are commonly used drugs as they are inexpensive and readily available. Based on these findings, more robust standardised surveillance is needed to confirm the patterns observed while recognizing the potential impact of sampling biases on observed resistance rates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Holistic Approach to Unravel Antibacterial Resistance in East Africa (HATUA) study, a 3-year Global Context Consortia Award (MR/S004785/1) was funded by the National Institute for Health Research, Medical Research Council and the Department of Health and Social Care. The award is also part of the EDCTP2 program supported by the European Union. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Scientific Ethical Review Committee of Kenya Medical Research Institute gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors